biopharma-reporter4h
nChroma Bio formed by merging genetic medicine companies
The merger of Nvelop Therapeutics and Chroma Medicine brings together a combination of epigenetic editing and in vivo ...
biopharma-reporter5h
SpliceBio gets FDA green light to start Phase 1/2 trial for inherited eye disease gene therapy
Enrollment in the Phase 1/2 ASTRA study is set to start in the first half of 2025. The study will observe the safety and ...
biopharma-reporter2d
Eli Lilly invests $3bn in injectable drug manufacturing facility
Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...
biopharma-reporter2d
Relation and GSK join forces to advance fibrotic diseases and osteoarthritis therapies
Big pharma company GSK and UK AI-biotech Relation Therapeutics have entered into two strategic collaborations to identify and ...
biopharma-reporter2d
GSK and Muna Therapeutics partner to develop new treatments for Alzheimer’s
The partnership revolves around Muna Therapeutics’ technology platform, which employs a spatial multi-omics approach to ...
biopharma-reporter7d
Cell and gene therapy access model launches in US
The sickle cell gene therapies developed by Bluebird Bio and Vertex will be the first to be offered under the new scheme.
biopharma-reporter7d
Antag Therapeutics raises $84 million to advance its weight loss drug into the clinic
The Danish biotech company Antag Therapeutics announced yesterday that it had raised €80 million ($84 million) in a Series A ...
biopharma-reporter9d
Spyre Therapeutics launches Phase 1 trials for its extended half-life IBD therapy
The U.S. biotech company Spyre Therapeutics announced yesterday that it has dosed the first participants in two Phase 1 ...
biopharma-reporter9d
PTC Therapeutics boosted by Novartis rights deal for Huntington’s program
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...